New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:20 EDTRDHLRedHill Biopharma announces commencement of bioavailability study of RHB-103
RedHill Biopharma together with IntelGenx announced the commencement of a comparative bioavailability clinical study comparing RHB-103 to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application for RHB-103, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. Results of the bioavailability study are anticipated by June.
News For RDHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
08:11 EDTRDHLRedHill receives Notice of Allowance for RHB-104 patent from USPTO
Subscribe for More Information
February 9, 2016
08:08 EDTRDHLRedHill Biopharma says scheduled to meet with FDA in early April
Subscribe for More Information
February 8, 2016
08:08 EDTRDHLRedHill Biopharma announces collaboration with Fraunhofer Institute for RP101
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use